Boston Scientific (BSX)
(Delayed Data from NYSE)
$105.41 USD
+0.49 (0.47%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $105.40 -0.01 (-0.01%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth C Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BSX 105.41 +0.49(0.47%)
Will BSX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BSX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BSX
OPK Stock Slips Following Q2 Earnings Miss, Gross Margin Expands
TMDX Stock Gains Post Q2 Earnings & Revenue Beat, Margins Up
BSX: What are Zacks experts saying now?
Zacks Private Portfolio Services
GEHC vs. BSX: Which Stock Is the Better Value Option?
Is It Worth Investing in Boston Scientific (BSX) Based on Wall Street's Bullish Views?
Resmed Q4 Earnings & Revenues Beat Estimates, Stock Up, Margins Climb
Other News for BSX
Beyond the Balance Sheet: What SWOT Reveals About Boston Scientific Corp (BSX)
1 ETF That Has Beaten The S&P Since Inception And 1 New ETF That Yields Over 12%
See Which Of The Latest 13F Filers Holds BSX
Insider Sell: Yoshiaki Fujimori Sells Shares of Boston Scientific Corp (BSX)
What's Driving the Market Sentiment Around Boston Scientific?